NICE issued a final determination in December 2013, recommending teriflunomide for treating adults with active relapsing–remitting MS (normally defined as 2 clinically significant relapses in the previous 2 years), only if they do not have highly active or rapidly evolving severe relapsing-remitting MS, and the manufacturer provides teriflunomide with the discount agreed in the patient access scheme. Final guidance is expected to be published later this month (January 2014).